Form 4: C4 Therapeutics Director Kenneth Anderson Acquires Shares as Compensation

C4 Therapeutics, Inc. Director Kenneth Carl Anderson acquired 7,616 shares of common stock at $1.51 per share on July 1, 2025, as part of his non-employee director compensation.

Summary

• Kenneth Carl Anderson, a Director of C4 Therapeutics, Inc. (CCCC), acquired 7,616 shares of common stock on July 1, 2025.
• The shares were acquired at a price of $1.51 per share, which was the closing market price on the transaction date.
• This acquisition was in accordance with the Issuer's Non-Employee Director Compensation Policy, where the reporting person elected to receive shares in lieu of cash compensation for his services.
• Following this transaction, Kenneth Carl Anderson directly beneficially owns 135,225 shares of common stock.
• Indirect beneficial ownership includes 47,316 shares held by his spouse, 61,265 shares by the Kenneth C. Anderson 2016 Grantor Retained Annuity Trust, 61,265 shares by the Cynthia E. Anderson 2016 Grantor Retained Annuity Trust, 16,939 shares by the Kenneth C. Anderson 2015 Irrevocable Trust, and 16,939 shares by the Cynthia E. Anderson 2015 Irrevocable Trust.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a director increasing their stake, even through compensation, generally signals alignment with shareholder interests. However, it is a routine compensation event rather than a discretionary open-market purchase, limiting its significant positive impact.

Positives

• The acquisition of shares by a director, even as compensation, aligns the director's interests more closely with those of the shareholders, potentially indicating confidence in the company's future.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

This filing represents a routine compensation event for a non-employee director within the biotechnology or pharmaceutical industry, reflecting standard corporate governance practices for aligning director incentives with company performance.

Related Party Transactions

• Shares are indirectly held by the Kenneth C. Anderson 2016 Grantor Retained Annuity Trust, Cynthia E. Anderson 2016 Grantor Retained Annuity Trust, Kenneth C. Anderson 2015 Irrevocable Trust, and Cynthia E. Anderson 2015 Irrevocable Trust. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders: The transaction increases the director's equity stake, potentially enhancing alignment between management and shareholder interests.

Key Dates

Keywords

C4 Therapeutics, CCCC, Form 4, insider transaction, director compensation, stock acquisition, Kenneth Anderson